Effects of vasoactive intestinal peptide on the infarct volume in rat transient focal cerebral Ischemia

Zhaohua Zhao,Xiaodan Hu,Jie Yang,Yihua Qian,Fen Qiu,Yong Liu
DOI: https://doi.org/10.3969/j.issn.1671-8259.2007.05.006
2007-01-01
Abstract:Objective: To explore the neuroprotective effects of vasoactive intestinal peptide (VIP) on ischemic brain injury in vivo. Methods: In the present study, VIP was given via intracerebroventriclar injection, and then focal cerebral ischemia was induced in SD rats by intraluminal occlusion of middle cerebral artery (MACO) for 120 min. The evaluation and screening of rats with successful occlusion of MCA were performed by neurological testing. The infarct volume was investigated with 2, 3, 5-triphenyltetrazolium chloride (TTC) stain. S100 β concentration in serum was detected by double-antibodies-sandwich-ELISA method. Results: The different grades of neurological severity appeared obviously in all the rats at 2 hours after MCAO. Only two rats that scored grade 1 or 2 had identifiable areas of infarction, whereas the areas of infarction in all the rats that were scored grade 3 were identified. Compared to the control groups at 1 day, injection of VIP significantly reduced the relative infarct volume by approximately 25% (P<0.05), and then remarkably decreased S100 β serum concentration (P<0.05). Conclusion: The grade 3 of neurological score as a standard to evaluate successful occlusion of MCA is satisfactory and reliable. VIP injection can reduce the infarct volume in a rat model of focal cerebral ischemia. The present study provides further evidence for the neuroprotective effects of VIP in vivo. VIP may decrease S100 β serum concentration, which may involve one of the mechanisms of the neuroprotective effect of VIP.
What problem does this paper attempt to address?